Placeholder Banner

BIO Joins Efforts to Aid in Humanitarian Relief in Ukraine

March 2, 2022
Media Contact
Connor McKoy
202.312.9288

The following statement can be attributed to BIO’s President and CEO Dr. Michelle McMurry-Heath in response to the ongoing conflict in Ukraine and the organization’s efforts to help in humanitarian relief:

“The conflict in Ukraine and violence from Russia defies international law, norms and modern sensibilities. Unfortunately, those suffering the most are individuals and families across Ukraine as they endure tremendous hardship and threats from immediate military attack, as well as interruptions to their ongoing medical treatments.

“In response, the biotechnology industry is working to donate a range of critical medical supplies, equipment, and medications to the people of Ukraine to help reduce their suffering. We are inspired by Ukrainians’ strength and resilience in this difficult hour and are committed to supporting them and standing with the international community against this unwarranted and life-threatening aggression.”

Below is a list of medications and medical supplies and equipment which have been requested.  Please note: we are ONLY trying to connect the Ukrainian Government with major corporate/manufacturer level donations at this time.

This effort is being led by the U.S. Department of Commerce, U.S. Commercial Service and is being coordinated by the U.S. Embassy in Ankara, Turkey. U.S. Commercial Service Officer, Andrew Glass, can answer any questions you may have.    

Andrew Glass

Commercial Officer, U.S. Embassy Ankara, Turkey

They are accepting donations from anywhere, and in particular are hoping that entities with a footprint in Europe will consider making donations given the geographic proximity in order to expedite these donations to the citizens of Ukraine. 

CRITICAL NEEDS:

  • Stomach wash kit
  • Set for catheterization of the bladder
  • Traction tire
  • Portable oxygen cylinders
  • Central vein catheterization kits
  • Set for intraosseous access
  • Kits for lumbar puncture
  • Tracheostomy set
  • Tracheal intubation kit
  • Set for drainage of the pleural cavity
  • Immobilization tires of various types and sizes
  • Syringes with needles (different volumes)
  • Catheters for peripheral veins (different sizes)
  • System for transfusion of infusion solutions
  • Non - sterile bandage (different sizes)
  • Elastic fixing bandage (different sizes)
  • Sterile material for anti-burn measures
  • Sterile material for wound surface treatment
  • Hydrogel anti-burn bandage of different sizes
  • External fixation device

 Name:

  • Paracetamol 500 mg
  • Meloxicam 7,5 mg
  • Ciprofloxacin 500 mg or Levofloxacin 500 mg
  • Individual sterile dressing package with elastic first aid compression component with protective moisture-resistant shell (Israeli Emergency Bandage 6) High priority
  • Bandages
  • Chemical means for a stop of bleeding (bandage hemostatic tamponing with hemostatic means) (QUIK CLOT) 2d priority
  • Gel-based occlusive thoracic bandage (sticker) (with or without valve)
  • Adhesive plaster
  • Medical gloves non sterile
  • Thermo blanket
  • Tourniqet «СAT» (Mechanical means for a stop of bleeding like "CAT") High priority
  • Tourniqet «SWAT» High priority
  • Nasopharyngeal airway (airway, tube)
  • Waterproof marker (blue)
  • Scissors for cutting clothes and shoes (atraumatic)

 To read the multi-industry letter, click here.

 

Discover More
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…
WASHINGTON – BIO President & CEO John F. Crowley released the following statement on the results of the 2024 U.S. election:“We look forward to working closely with President-elect Trump, his incoming Administration, and members of Congress on…
July 17, 2024 – BIO President and CEO John F. Crowley today released the following statement after the U.S. Food & Drug Administration (FDA) announced a plan to establish a Rare Disease Innovation Hub that will utilize new and collaborative…